Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical comp...
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulso...
Bausch Health Companies (TSX:BHC) reported quarterly earnings of $0.91 per share which missed the analyst consensus estimate of...
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the...
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindam...
RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (TSX:BHC) with a Sector Perform and raises the price tar...
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 M...
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relent...
RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (TSX:BHC) with a Neutral and lowers the price target fro...
